Compare WLK & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WLK | QGEN |
|---|---|---|
| Founded | 1986 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.3B | 8.7B |
| IPO Year | 2004 | 1998 |
| Metric | WLK | QGEN |
|---|---|---|
| Price | $78.64 | $44.75 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 8 |
| Target Price | ★ $106.87 | $45.76 |
| AVG Volume (30 Days) | 1.2M | ★ 2.7M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | 1.90% | ★ 7.17% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.70 | N/A |
| Revenue | ★ $11,170,000,000.00 | N/A |
| Revenue This Year | $5.51 | $8.18 |
| Revenue Next Year | $3.74 | $5.71 |
| P/E Ratio | $113.50 | ★ $24.01 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $56.33 | $32.53 |
| 52 Week High | $124.23 | $57.82 |
| Indicator | WLK | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 53.69 | 67.59 |
| Support Level | $77.58 | $44.61 |
| Resistance Level | $90.28 | $46.17 |
| Average True Range (ATR) | 2.96 | 1.02 |
| MACD | 0.39 | 0.09 |
| Stochastic Oscillator | 84.04 | 87.45 |
Westlake is a forward-integrated commodity chemicals firm based in Houston. It began as a single low-density polyethylene plant and expanded its capabilities to include ethylene, vinyl chloride monomers, and polyvinyl chloride over the next two decades. The acquisition of Axiall in 2016 made it a North American leader in chlor-alkali and PVC. Today, Westlake has two defined segments: performance and essential materials, and housing and infrastructure products. The HIP segment began operating in 2022 following a series of acquisitions in the building products space. The firm aims to maximize the value of its chemical production by integrating with the HIP segment, realizing the higher margins of finished commercial goods.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).